GlaxoSmithKline Pharmaceuticals Limited GLAXO NIFTY_MIDNSEPHARMA
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 49.1%.
- Healthy ROCE of 55.4%.
- Excellent profit margin of 27.1%.
- Profit CAGR of 19.3% over 5 years.
- Attractive dividend yield of 2.58%.
- Generates positive free cash flow.
CONS
- Trading 36.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLAXO GlaxoSmithKline Pharmaceuticals Limited NIFTY_MIDNSEPHARMA | 2,210.20 | 36.76 | ₹37,442.12 Cr | 2.58% | 55.36% | 49.11% | 5.81% | 19.26% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 949.42 Cr | 974.37 Cr | 805.17 Cr | 1,041.26 Cr | 995.30 Cr |
| Cost of Revenue | - | 359.16 Cr | 351.94 Cr | 287.71 Cr | 363.82 Cr | 344.00 Cr |
| Gross Profit | - | 590.26 Cr | 622.43 Cr | 517.46 Cr | 677.44 Cr | 651.30 Cr |
| Operating Expenses | - | 317.14 Cr | 303.96 Cr | 281.78 Cr | 326.42 Cr | 313.54 Cr |
| Operating Income | - | 273.12 Cr | 318.47 Cr | 235.68 Cr | 351.02 Cr | 337.76 Cr |
| EBITDA | - | 326.99 Cr | 373.87 Cr | 294.92 Cr | 421.44 Cr | 386.88 Cr |
| Interest Expense | - | 9.00 L | 58.00 L | 42.00 L | 1.19 Cr | 61.00 L |
| Pretax Income | - | 308.10 Cr | 358.57 Cr | 278.98 Cr | 399.93 Cr | 373.10 Cr |
| Tax Provision | - | 78.22 Cr | 95.70 Cr | 73.97 Cr | 104.31 Cr | 95.24 Cr |
| Net Income | - | 229.88 Cr | 262.87 Cr | 205.01 Cr | 295.62 Cr | 277.86 Cr |
| Diluted EPS | - | 13.57 | 15.52 | 12.10 | 17.45 | 16.40 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 3,226.38 Cr | 3,441.77 Cr | 3,749.21 Cr | 3,821.67 Cr |
| Cost of Revenue | - | 1,358.72 Cr | 1,419.85 Cr | 1,390.86 Cr | 1,351.06 Cr |
| Gross Profit | - | 1,867.66 Cr | 2,021.92 Cr | 2,358.35 Cr | 2,470.61 Cr |
| Operating Expenses | - | 1,119.23 Cr | 1,183.44 Cr | 1,247.78 Cr | 1,227.85 Cr |
| Operating Income | - | 748.43 Cr | 838.49 Cr | 1,110.57 Cr | 1,242.76 Cr |
| EBITDA | - | 903.98 Cr | 887.67 Cr | 1,327.98 Cr | 1,475.18 Cr |
| Interest Expense | - | 1.81 Cr | 1.80 Cr | 1.31 Cr | 2.73 Cr |
| Pretax Income | - | 836.40 Cr | 816.19 Cr | 1,259.88 Cr | 1,406.01 Cr |
| Tax Provision | - | 228.76 Cr | 226.23 Cr | 332.30 Cr | 370.03 Cr |
| Net Income | - | 610.69 Cr | 589.96 Cr | 927.58 Cr | 1,035.98 Cr |
| Diluted EPS | 100.04 | 36.05 | 34.83 | 54.52 | - |
Compounded Sales Growth
| 5 Years: | 5.81% |
| 1 Year: | 2.10% |
Compounded Profit Growth
| 5 Years: | 19.26% |
| 1 Year: | 5.70% |
Stock Price Performance
| 1 Year: | -31.39% |
| 6 Months: | -10.77% |
| 3 Months: | -16.24% |
| 1 Month: | -6.61% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 3,326.58 Cr | 3,556.62 Cr | 4,108.07 Cr | 4,323.87 Cr |
| Current Assets | - | 2,494.26 Cr | 2,798.42 Cr | 3,409.88 Cr | 3,607.05 Cr |
| Cash & Equivalents | - | 34.94 Cr | 64.17 Cr | 538.85 Cr | 1,102.05 Cr |
| Inventory | - | 459.97 Cr | 525.05 Cr | 481.74 Cr | 457.55 Cr |
| Receivables | - | 192.38 Cr | 222.06 Cr | 292.55 Cr | 273.11 Cr |
| Total Liabilities | - | 1,585.31 Cr | 1,778.98 Cr | 2,156.75 Cr | 2,056.45 Cr |
| Current Liabilities | - | 1,326.37 Cr | 1,524.95 Cr | 1,905.15 Cr | 1,779.11 Cr |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 15.54 Cr | 18.66 Cr | 9.95 Cr | 33.27 Cr |
| Total Equity | - | 1,741.27 Cr | 1,777.64 Cr | 1,951.31 Cr | 2,267.42 Cr |
| Shares Outstanding | - | 16.94 Cr | 16.94 Cr | 16.94 Cr | 16.94 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 484.23 Cr | 582.02 Cr | 1,289.91 Cr | 903.30 Cr |
| Investing Cash Flow | - | 807.85 Cr | 8.71 Cr | -45.81 Cr | 396.98 Cr |
| Financing Cash Flow | - | -1,543.32 Cr | -561.50 Cr | -769.42 Cr | -737.08 Cr |
| Capital Expenditure | - | -44.04 Cr | -31.22 Cr | -24.72 Cr | -55.28 Cr |
| Free Cash Flow | - | 440.19 Cr | 550.79 Cr | 1,265.19 Cr | 848.02 Cr |
| Net Change in Cash | - | -251.25 Cr | 29.23 Cr | 474.68 Cr | 563.20 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 57.9% | 58.7% | 62.9% | 64.6% |
| Operating Margin % | - | 23.2% | 24.4% | 29.6% | 32.5% |
| Net Margin % | - | 18.9% | 17.1% | 24.7% | 27.1% |
| ROE % | - | 35.1% | 33.2% | 47.5% | 45.7% |
| ROCE % | - | 37.4% | 41.3% | 50.4% | 48.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GLAXO